Vladimir Coric
Chief Executive Officer bei BIOHAVEN LTD.
Vermögen: 172 Mio $ am 31.03.2024
Profil
Dr. Vlad Coric, MD, ist Chief Executive Officer & Director bei Biohaven Pharmaceutical Holding Co. Ltd. und ein außerordentlicher klinischer Professor an der Yale School of Medicine. Er ist Mitglied des Verwaltungsrats von Biohaven Pharmaceutical Holding Co. Ltd., der Our Lady of Mercy Academy, Pyramid Biosciences, Inc. und Vita Therapeutics, Inc. Dr. Coric war zuvor als Group Director-Global Clinical Research bei Bristol Myers Squibb Co. und als Präsident der Connecticut Psychiatric Society tätig. Er erhielt seinen Doktortitel von der Wake Forest School of Medicine.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
BIOHAVEN LTD.
3,85% | 22.04.2024 | 3 146 085 ( 3,85% ) | 172 Mio $ | 31.03.2024 |
08.03.2024 | 5 784 ( 0,01% ) | 28 457 $ | 31.03.2024 |
Aktive Positionen von Vladimir Coric
Unternehmen | Position | Beginn |
---|---|---|
BIOHAVEN LTD. | Chief Executive Officer | 02.05.2022 |
REVANCE THERAPEUTICS, INC. | Director/Board Member | 01.03.2023 |
Yale School of Medicine | Corporate Officer/Principal | 01.07.2001 |
Vita Therapeutics, Inc.
Vita Therapeutics, Inc. BiotechnologyHealth Technology Vita Therapeutics, Inc. is a biotechnology company based in Baltimore, MD that develops state-of-the-art cellular therapeutics for the treatment of neuromuscular diseases and cancers. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics is progressing its co-leading programs VTA-100 and VTA-300 for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors with the goal of filing investigational drug applications with the Food and Drug Administration in 2023. The company is developing these proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics was founded in 2019 by Douglas Taylor Falk, M.S. and Peter Andersen, Ph.D. Douglas Taylor Falk has been the CEO since 2019. | Director/Board Member | - |
Our Lady of Mercy Academy | Director/Board Member | - |
Pyramid Biosciences, Inc.
Pyramid Biosciences, Inc. BiotechnologyHealth Technology Pyramid Biosciences, Inc. operates as a biotechnology company. It develops new therapies focused on the modulation of cell surface. The company was founded by Kollol Pal and Jordan Leef and is headquartered in Waltham, MA. | Director/Board Member | - |
Biohaven Pharmaceuticals, Inc.
Biohaven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT. | Chief Executive Officer | - |
Veradermics, Inc.
Veradermics, Inc. Pharmaceuticals: MajorHealth Technology VeraDermics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing drugs for immunologic and dermatologic diseases. The company is based in San Antonio, TX. The company has a portfolio of five product candidates that target common skin conditions such as warts, hair loss, and eczema. Founded by dermatologists, VeraDermics leverages its clinical experience to identify and advance novel drugs that address specific patient needs and solve pervasive treatment challenges in dermatology practice. | Director/Board Member | - |
Ehemalige bekannte Positionen von Vladimir Coric
Unternehmen | Position | Ende |
---|---|---|
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Chief Executive Officer | 03.10.2022 |
░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░ | - |
Ausbildung von Vladimir Coric
Wake Forest School of Medicine | Doctorate Degree |
University of Connecticut | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
REVANCE THERAPEUTICS, INC. | Health Technology |
BIOHAVEN LTD. | Health Technology |
Private Unternehmen | 8 |
---|---|
Biohaven Pharmaceutical Holding Co. Ltd.
Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
Our Lady of Mercy Academy | |
Connecticut Psychiatric Society | |
Biohaven Pharmaceuticals, Inc.
Biohaven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT. | Commercial Services |
Pyramid Biosciences, Inc.
Pyramid Biosciences, Inc. BiotechnologyHealth Technology Pyramid Biosciences, Inc. operates as a biotechnology company. It develops new therapies focused on the modulation of cell surface. The company was founded by Kollol Pal and Jordan Leef and is headquartered in Waltham, MA. | Health Technology |
Vita Therapeutics, Inc.
Vita Therapeutics, Inc. BiotechnologyHealth Technology Vita Therapeutics, Inc. is a biotechnology company based in Baltimore, MD that develops state-of-the-art cellular therapeutics for the treatment of neuromuscular diseases and cancers. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics is progressing its co-leading programs VTA-100 and VTA-300 for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors with the goal of filing investigational drug applications with the Food and Drug Administration in 2023. The company is developing these proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics was founded in 2019 by Douglas Taylor Falk, M.S. and Peter Andersen, Ph.D. Douglas Taylor Falk has been the CEO since 2019. | Health Technology |
Veradermics, Inc.
Veradermics, Inc. Pharmaceuticals: MajorHealth Technology VeraDermics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing drugs for immunologic and dermatologic diseases. The company is based in San Antonio, TX. The company has a portfolio of five product candidates that target common skin conditions such as warts, hair loss, and eczema. Founded by dermatologists, VeraDermics leverages its clinical experience to identify and advance novel drugs that address specific patient needs and solve pervasive treatment challenges in dermatology practice. | Health Technology |
Social Capital Suvretta Holdings Corp. I
Social Capital Suvretta Holdings Corp. I Financial ConglomeratesFinance Social Capital Suvretta Holdings Corp. I is a blank check company, which engages in effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It focuses on the search for target business operating in the biotechnology industry and within the neurology subsector. The company was founded by Chamath Palihapitiya and Kishen C. Mehta on February 25, 2021 and is headquartered in Henderson, NV. | Finance |